Edward Woo

Emily Bodnar

- Atossa Therapeutics, Inc. released an updated corporate presentation on **September 26, 2025**, detailing the broad utility of its lead program, **(Z)-endoxifen**, for estrogen receptor positive breast cancer.  **[1488039_0001193125-25-220788_atos-ex9_1.htm:0]** **[1488039_0001193125-25-220788_atos-20250926.htm:1]** 
- The company maintains a strong financial position with **$57.9 million in cash** as of **June 30, 2025**, providing **over a year of runway and zero debt**.  **[1488039_0001193125-25-220788_atos-ex9_1.htm:1]** 
- Key upcoming milestones include a **505(b)(2) NDA filing for Prevention in 2026** and the **Project Optimus IND and dose-ranging study in Q4 2025**.  **[1488039_0001193125-25-220788_atos-ex9_1.htm:1]** 
- The FDA has affirmed the strategic approach for (Z)-endoxifen, confirming existing clinical and nonclinical data are sufficient for initiating Phase 2 monotherapy and aligning with Project Optimus for dosage optimization.  **[1488039_0001193125-25-220788_atos-ex9_1.htm:4]**

ATOSSA THERAPEUTICS (ATOS)